DURHAM, N.C., March 25, 2019 — Premier Research’s head of patient engagement will discuss a patient-centered look at drug development at the World Orphan Drug Congress (WODC) USA in Oxon Hill, Maryland.
Juliet Moritz, Premier Research’s newly appointed vice president of patient and stakeholder engagement (PASE), will present From the End to the Beginning: A Patient-Centric Look at Drug Development and Commercial Access on Thursday, April 11, at 12:15 p.m.
“The term ‘patient centricity’ is used more and more frequently when talking about the drug development process, and that’s a good thing,” Moritz said in introducing her topic. “But exactly what is patient-centric drug development, what are its goals, and how do we achieve them?”
Topics will include:
- Working backward to examine how early planning can improve the results of a development program
- Specific goals to factor into designing a drug development process
- Steps sponsors and their partners can take to create and implement development plans that deliver new treatments to patients who need them
As vice president of PASE, Moritz is the company’s internal expert on patient-focused research activities, helping clients develop and execute patient-centered research across the therapeutic spectrum.
Further demonstrating its commitment to patient engagement, Premier Research recently established a scholarship to promote rare disease advocacy. The company will send one person within the rare disease advocacy community to the Sanford/PPALS Patient Advocacy Certification Training program.
Premier Research is returning for its ninth year as a sponsor of WODC and the Pitch and Partner session. Visit https://premier-research.com/events/ for more information on this and other upcoming events.
About Premier Research
Premier Research, a midsize clinical research company, is dedicated to helping biotech, specialty pharma, and device innovators transform life-changing ideas and breakthrough science into new medical treatments.
As a global company, Premier Research specializes in the use of innovative technologies for smart study design and trial management to deliver clean, conclusive data to sponsors.
Whether it’s developing product lifecycle strategies, reducing clinical development cycle times, securing access to patients, navigating global regulations, maximizing the impact of limited rare disease data, or providing expertise in specific therapeutic areas, Premier Research is committed to helping its customers answer the unmet needs of patients across a broad range of medical conditions.